About this trial
Pulmonary vein re-isolation plus Vein of Marshall ethanol ablation in combination with block of mitral and tricuspid isthmuses and dome line will be compared to pulmonary vein re-isolation alone in patients undergoing re-ablation for persistent atrial fibrillation in this investigator initiated, randomized, patient-assessor blinded multicenter trial. Patients are followed with standard ECG at 3 months, with standard ECG, 5-days' ECG monitoring and quality of life assessment after 12 months, with standard ECG and quality of life assessment after 24 months, through patient files at 60 months after the ablation.
Primary endpoint: Change in AFEQT score between baseline and 12 months.
Eligibility criteria
Qualifiers
Previous pulmonary vein isolation for atrial fibrillation
Indication for catheter ablation with at least two episodes of symptomatic PsAF during the last 12 months
Age > 18 years
Expected survival > 12 months
Disqualifiers
Previous extrapulmonary atrial ablation other than cavotricuspid isthmus line, roof- or dome line or posterior wall isolation/ablation
Atypical atrial flutter in addition to atrial fibrillation
Atrial fibrillation secondary to a transient abnormality
Uncontrolled hypertension
Trial design
Treatments tested in this trial
- Intervention
- Control
Treatment groups
Sponsors and collaborators
Aarhus University Hospital
Lead sponsor
Karolinska University Hospital
Collaborator
Leiden University Medical Center
Collaborator